Cargando…

Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China

BACKGROUND: Metformin treatment is associated with vitamin B12 deficiency, which is a risk factor for neuropathy. However, few studies have examined the relationship between metformin treatment and diabetic peripheral neuropathy (DPN), and the available findings are contradictory. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ruotong, Yu, Huan, Wu, Junhui, Chen, Hongbo, Wang, Mengying, Wang, Siyue, Qin, Xueying, Wu, Tao, Wu, Yiqun, Hu, Yonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011647/
https://www.ncbi.nlm.nih.gov/pubmed/36926032
http://dx.doi.org/10.3389/fendo.2023.1082720
_version_ 1784906442646487040
author Yang, Ruotong
Yu, Huan
Wu, Junhui
Chen, Hongbo
Wang, Mengying
Wang, Siyue
Qin, Xueying
Wu, Tao
Wu, Yiqun
Hu, Yonghua
author_facet Yang, Ruotong
Yu, Huan
Wu, Junhui
Chen, Hongbo
Wang, Mengying
Wang, Siyue
Qin, Xueying
Wu, Tao
Wu, Yiqun
Hu, Yonghua
author_sort Yang, Ruotong
collection PubMed
description BACKGROUND: Metformin treatment is associated with vitamin B12 deficiency, which is a risk factor for neuropathy. However, few studies have examined the relationship between metformin treatment and diabetic peripheral neuropathy (DPN), and the available findings are contradictory. We aimed to assess whether metformin treatment is associated with DPN in patients with type 2 diabetes mellitus (T2DM) in Beijing, China. METHODS: All patients with newly diagnosed T2DM between January 2010 and September 2012 in the Medical Claim Data for Employees database were included. Metformin treatment was defined as any record of metformin prescription. The average daily dose of metformin during follow-up was calculated. DPN was defined as DPN admissions occurring after a diagnosis of T2DM in the database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. RESULTS: Among 49,705 T2DM patients, 1,933 DPN events were recorded during a median follow-up of 6.36 years. The crude incidence rates were 7.12 and 3.91 per 1000 person-years for patients treated with metformin (N=37,052) versus those not treated (N=12,653). Patients treated with metformin had an 84% increased risk of DPN compared with patients not using metformin (HR, 1.84; 95% CI, 1.62, 2.10). The daily dose was positively associated with DPN risk (HR, 1.48; 95% CI, 1.46, 1.51; P for trend <0.001). The risk of DPN was 1.53-fold (1.30, 1.81) and 4.31-fold (3.76, 4.94) higher in patients with daily doses of 1.0-2.0 g and >2.0 g, respectively, than in patients who did not receive treatment. Patients aged less than 60 years had a higher risk of DPN (P<0.05 for interaction test). Among patients taking vitamin B12 at baseline, there was no increased risk of DPN in the metformin group (1.92: 0.79, 4.69). CONCLUSIONS: In Chinese patients with T2DM, metformin treatment was associated with an increased risk of DPN admission and this risk responds positively to the daily dose of metformin. In particular, metformin use was a major risk factor for DPN in younger patients. Concomitant use of vitamin B12 may avoid the increased risk of DPN associated with metformin use.
format Online
Article
Text
id pubmed-10011647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100116472023-03-15 Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China Yang, Ruotong Yu, Huan Wu, Junhui Chen, Hongbo Wang, Mengying Wang, Siyue Qin, Xueying Wu, Tao Wu, Yiqun Hu, Yonghua Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Metformin treatment is associated with vitamin B12 deficiency, which is a risk factor for neuropathy. However, few studies have examined the relationship between metformin treatment and diabetic peripheral neuropathy (DPN), and the available findings are contradictory. We aimed to assess whether metformin treatment is associated with DPN in patients with type 2 diabetes mellitus (T2DM) in Beijing, China. METHODS: All patients with newly diagnosed T2DM between January 2010 and September 2012 in the Medical Claim Data for Employees database were included. Metformin treatment was defined as any record of metformin prescription. The average daily dose of metformin during follow-up was calculated. DPN was defined as DPN admissions occurring after a diagnosis of T2DM in the database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. RESULTS: Among 49,705 T2DM patients, 1,933 DPN events were recorded during a median follow-up of 6.36 years. The crude incidence rates were 7.12 and 3.91 per 1000 person-years for patients treated with metformin (N=37,052) versus those not treated (N=12,653). Patients treated with metformin had an 84% increased risk of DPN compared with patients not using metformin (HR, 1.84; 95% CI, 1.62, 2.10). The daily dose was positively associated with DPN risk (HR, 1.48; 95% CI, 1.46, 1.51; P for trend <0.001). The risk of DPN was 1.53-fold (1.30, 1.81) and 4.31-fold (3.76, 4.94) higher in patients with daily doses of 1.0-2.0 g and >2.0 g, respectively, than in patients who did not receive treatment. Patients aged less than 60 years had a higher risk of DPN (P<0.05 for interaction test). Among patients taking vitamin B12 at baseline, there was no increased risk of DPN in the metformin group (1.92: 0.79, 4.69). CONCLUSIONS: In Chinese patients with T2DM, metformin treatment was associated with an increased risk of DPN admission and this risk responds positively to the daily dose of metformin. In particular, metformin use was a major risk factor for DPN in younger patients. Concomitant use of vitamin B12 may avoid the increased risk of DPN associated with metformin use. Frontiers Media S.A. 2023-02-28 /pmc/articles/PMC10011647/ /pubmed/36926032 http://dx.doi.org/10.3389/fendo.2023.1082720 Text en Copyright © 2023 Yang, Yu, Wu, Chen, Wang, Wang, Qin, Wu, Wu and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Yang, Ruotong
Yu, Huan
Wu, Junhui
Chen, Hongbo
Wang, Mengying
Wang, Siyue
Qin, Xueying
Wu, Tao
Wu, Yiqun
Hu, Yonghua
Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title_full Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title_fullStr Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title_full_unstemmed Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title_short Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China
title_sort metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in beijing, china
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011647/
https://www.ncbi.nlm.nih.gov/pubmed/36926032
http://dx.doi.org/10.3389/fendo.2023.1082720
work_keys_str_mv AT yangruotong metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT yuhuan metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT wujunhui metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT chenhongbo metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT wangmengying metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT wangsiyue metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT qinxueying metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT wutao metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT wuyiqun metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina
AT huyonghua metformintreatmentandriskofdiabeticperipheralneuropathyinpatientswithtype2diabetesmellitusinbeijingchina